EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Effect of Hemodialysis on Total and Free Lenvatinib Concentrations in a Patient With Metastatic Renal Cell Carcinoma

Takahiro Ito, Shimpei Yamashita, Manabu Suno, Ayaka Iwata, Yasuo Kohjimoto, Kazuo Matsubara

IJU Case Reports · 2025-11 · 8 (6) · 601-603

DOI: 10.1002/iju5.70099 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Introduction Lenvatinib (LEN) concentrations in patients undergoing hemodialysis (HD) have not been examined. Herein, we report the effect of HD on total and free LEN concentrations in a patient with mRCC. Case Presentation The hemodialyzed patient was a 55‐year‐old Japanese male who was treated with 20 mg LEN daily. The area under the plasma concentration–time curve for LEN from 0 to 24 h (AUC 0–24 ) was calculated on Day 8 (off HD) and Day 9 (on HD) after starting administration of LEN. For total LEN on Days 8 and 9, the AUC 0–24 was 2553 and 2783 ng × h/mL, respectively. The free LEN concentration just after HD on Day 9 was 40% lower than that at the same time on Day 8 (1.8 vs. 3.0 ng/mL). Conclusion Although the free LEN concentration is reduced just after HD, LEN will have sufficient pharmacological activity on HD days for patients undergoing HD.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →